Current Research in Translational Medicine

Scope & Guideline

Fostering Collaboration in Cutting-Edge Medical Research

Introduction

Welcome to your portal for understanding Current Research in Translational Medicine, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN2452-3186
PublisherELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
Support Open AccessNo
CountryFrance
TypeJournal
Convergefrom 2016 to 2024
AbbreviationCURR RES TRANSL MED / Curr. Res. Transl. Med.
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE

Aims and Scopes

Current Research in Translational Medicine focuses on bridging the gap between laboratory research and clinical applications, with a strong emphasis on hematological malignancies and innovative therapies. The journal aims to publish high-quality research that contributes to the understanding and management of various medical conditions, particularly through translational approaches.
  1. Hematological Malignancies:
    The journal consistently publishes research related to hematological cancers, including acute myeloid leukemia, lymphoma, and multiple myeloma, focusing on novel treatments and therapeutic strategies.
  2. Translational Research:
    A core aim is to translate laboratory findings into clinical applications, emphasizing studies that bridge experimental and clinical medicine.
  3. Cell and Gene Therapy:
    Research on cell-based therapies, particularly CAR-T cell therapy and stem cell transplantation, is a significant focus, highlighting advancements in treatment methodologies.
  4. Immunotherapy:
    The journal covers emerging immunotherapeutic strategies, investigating their efficacy and safety in treating various malignancies.
  5. Biomarkers and Diagnostics:
    There is a strong emphasis on identifying biomarkers for disease prognosis and treatment response, contributing to personalized medicine.
  6. Regenerative Medicine:
    Research involving stem cells and regenerative therapies is prevalent, showcasing innovative approaches to repair and regenerate damaged tissues.
  7. Clinical Guidelines and Best Practices:
    The journal also addresses clinical practices through guidelines and recommendations for managing hematological disorders.
Current Research in Translational Medicine is witnessing a surge in certain emerging themes that reflect the evolving landscape of medical research. This section outlines these trending areas, which are gaining prominence in recent publications.
  1. CAR-T Cell and Novel Immunotherapies:
    The increasing focus on CAR-T cell therapy and other immunotherapeutic approaches highlights the journal's commitment to cutting-edge treatments and their applications in hematological malignancies.
  2. Next-Generation Sequencing and Genomics:
    There is a growing trend towards incorporating genomic technologies such as next-generation sequencing, which aids in understanding the genetic underpinnings of diseases and personalizing treatment.
  3. Biomarker Discovery and Application:
    Research aimed at discovering and validating biomarkers for various hematological conditions is on the rise, enhancing the capabilities of precision medicine.
  4. Artificial Intelligence and Data Analytics:
    The integration of AI and data analytics in predicting treatment outcomes and patient responses is emerging as a significant trend, reflecting the journal's adaptation to technological advancements.
  5. Regenerative and Stem Cell Therapies:
    An increasing number of studies are exploring the potential of regenerative medicine and stem cell therapies, indicating a shift towards innovative approaches in treatment.
  6. Clinical Guidelines and Evidence-Based Practices:
    There is a noticeable trend towards publishing clinical guidelines and recommendations, aiming to standardize practices and improve patient care in hematological oncology.

Declining or Waning

While Current Research in Translational Medicine maintains a robust focus on hematological disorders and innovative therapies, certain themes have shown signs of decline in recent publications. This section highlights these waning areas.
  1. Solid Tumor Research:
    Research specifically focused on solid tumors has decreased, indicating a shift towards hematological malignancies and therapies related to blood cancers.
  2. Traditional Pharmacotherapy:
    There appears to be a reduction in studies centered on conventional pharmacological treatments, as innovative therapies like immunotherapy and gene therapy become more prominent.
  3. Infectious Disease Research:
    While COVID-19 research was significant during the pandemic, the volume of papers addressing infectious diseases outside the context of hematological malignancies has lessened.
  4. Basic Science Studies:
    There is a noticeable decline in purely basic science research that does not directly translate to clinical applications, as the journal increasingly emphasizes translational studies.

Similar Journals

Blood Science

Pioneering Research for Better Blood Health
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 2543-6368Frequency:

Blood Science is a distinguished peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the dynamic field of hematology. Since its inception, the journal has aimed to disseminate high-quality research and innovative findings that contribute to our understanding of blood-related health issues. With the ISSN 2543-6368, it offers a platform for academic discussions and breakthroughs in various subfields including hematopathology, blood disorders, and transfusion medicine. As of 2023, Blood Science is ranked in the third quartile (Q3) within the hematology category, indicating a burgeoning influence among its peers, with a Scopus rank of #101 out of 137 journals, placing it in the 26th percentile. Although it is not an open-access journal, it provides essential insights and valuable data for researchers, healthcare professionals, and students alike, enhancing the collective knowledge and practices in hematology. With a publication period spanning from 2019 to 2024, Blood Science remains committed to fostering the advancement of blood science research and enhancing patient care methodologies.

Revista Romana de Medicina de Laborator

Unveiling the Future of Laboratory Medicine
Publisher: SCIENDOISSN: 1841-6624Frequency: 4 issues/year

Revista Romana de Medicina de Laborator is a prominent open-access journal published by SCIENDO, dedicated to the field of medical laboratory technology and biochemistry. Since its inception, this journal has been a vital platform for disseminating research findings and advancements in laboratory medicine. With an ISSN of 1841-6624 and E-ISSN 2284-5623, it has served the academic community since 2008 and has embraced an open-access model since 2013, ensuring that valuable research is accessible to all. While it features niche rankings in Scopus for areas such as Medical Laboratory Technology and Clinical Biochemistry, it consistently strives to engage researchers, professionals, and students. Its rich collection of articles highlights innovative techniques and methodologies, supporting the ongoing development of laboratory practices. Although its coverage in Scopus has been discontinued, the journal continues to publish high-quality studies that contribute significantly to the field, fostering knowledge exchange essential for advancing medical science.

Nature Reviews Clinical Oncology

Exploring Breakthroughs in Clinical Oncology
Publisher: NATURE PORTFOLIOISSN: 1759-4774Frequency: 12 issues/year

Nature Reviews Clinical Oncology is a premier journal dedicated to the comprehensive exploration and critical evaluation of current advancements in the field of clinical oncology. Published by the esteemed NATURE PORTFOLIO in the United Kingdom, this influential journal boasts an impressive impact factor that reflects its significant role in shaping oncology research. As a Q1 ranked journal in Scopus, it occupies a notable position within the top tier of oncology publications, placing it in the 99th percentile among its peers. With a history of convergence from 2009 to 2024, it presents high-quality content through an open-access model, ensuring accessibility to vital research findings. Researchers, professionals, and students alike will find Nature Reviews Clinical Oncology an invaluable resource for staying abreast of the latest trends, biologic insights, and therapeutic innovations that drive the future of cancer treatment.

BONE MARROW TRANSPLANTATION

Unveiling New Horizons in Bone Marrow Transplantation.
Publisher: SPRINGERNATUREISSN: 0268-3369Frequency: 12 issues/year

BONE MARROW TRANSPLANTATION, published by SpringerNature, stands as a leading journal in the fields of Hematology and Transplantation, as evidenced by its recognition in the Q1 category for both disciplines according to 2023 rankings. With an impressive impact factor and notable Scopus rankings—7th out of 54 in Medicine Transplantation and 25th out of 137 in Medicine Hematology—this journal is instrumental for researchers and professionals dedicated to advancements in bone marrow transplantation practices and research. Established in 1986, the journal publishes original research, clinical studies, and reviews that push the boundaries of current knowledge, making it essential reading for those looking to stay abreast of the latest developments in the field. Although offering limited Open Access options, BONE MARROW TRANSPLANTATION reaches a broad audience and furthers a global dialogue on best practices and innovative approaches in transplantation medicine. Its address in London, UK positions it at the heart of international research collaboration, fostering connections among scientists, clinicians, and students alike.

CURRENT OPINION IN HEMATOLOGY

Empowering clinicians and researchers with cutting-edge insights.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1065-6251Frequency: 6 issues/year

CURRENT OPINION IN HEMATOLOGY is a leading peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the latest advancements and insights in the field of hematology. With an impressive impact factor and ranked in the first quartile (Q1) of its category, this journal serves as a vital resource for researchers, clinicians, and students seeking to stay informed on contemporary issues and emerging trends in hematological research and treatment. Established in 1994, it showcases critical reviews, expert commentary, and systematic analyses across a broad spectrum of hematology topics, contributing significantly to clinical and experimental knowledge through its robust editorial standards. While offering traditional subscription access, CURRENT OPINION IN HEMATOLOGY remains committed to providing a platform that bridges the gap between fundamental research and clinical application, making it indispensable for professionals dedicated to advancing patient care and scientific understanding in hematology.

Journal of Hematology & Oncology

Pioneering Discoveries in Hematology and Oncology
Publisher: BMCISSN: Frequency: 1 issue/year

Journal of Hematology & Oncology, published by BMC, is a leading open-access journal dedicated to the dynamic fields of hematology and oncology, with a continuous publication record since 2008. Based in the United Kingdom, this prestigious journal provides a platform for groundbreaking research, encompassing topics that span cancer research, hematological disorders, and molecular biology. With a remarkable Q1 ranking in multiple categories including Cancer Research, Hematology, Molecular Biology, and Oncology for 2023, it stands as a significant contributor to the scientific community. The journal's rigorous peer-review process ensures the dissemination of high-quality studies that drive advancements in these critical areas of medicine, boasting an impressive Scopus rank in the top echelons of its fields. As an open-access publication, it promotes widespread accessibility and sharing of knowledge, making it an indispensable resource for researchers, clinicians, and students striving to make advancements in understanding and treating hematological and oncological diseases.

HEMATOLOGICAL ONCOLOGY

Shaping the Future of Cancer Treatment and Research
Publisher: WILEYISSN: 0278-0232Frequency: 4 issues/year

HEMATOLOGICAL ONCOLOGY, published by Wiley, is a premier journal in the fields of cancer research, hematology, and oncology, with a rich history of publication dating back to 1983. With an impact factor indicative of its influential standing—ranking in the second quartile in multiple categories including Cancer Research, Hematology, and Oncology—this journal serves as a vital resource for researchers, clinicians, and students alike. HEMATOLOGICAL ONCOLOGY is based in the United Kingdom and focuses on the advancements and challenges in the understanding and treatment of hematological malignancies. While it does not offer open access options, its rigorous peer-review process ensures that all published articles are of the highest quality, contributing to the ongoing dialogue and research in this critical area of medicine. With its commitment to disseminating impactful research, HEMATOLOGICAL ONCOLOGY remains an essential platform for driving innovation and collaboration within the global scientific community.

npj Regenerative Medicine

Shaping the Future of Therapeutic Advancements.
Publisher: NATURE PORTFOLIOISSN: Frequency: 1 issue/year

npj Regenerative Medicine, published by NATURE PORTFOLIO, is at the forefront of research and innovation in the field of regenerative medicine, fostering a deep understanding of cellular and molecular processes that can be leveraged for therapeutic advancements. Launched as an Open Access journal since 2016, it ensures wide dissemination of knowledge, allowing researchers, professionals, and students to access high-quality articles without barriers. With an impressive impact, it holds Q1 ratings across multiple categories including Biomedical Engineering, Cell Biology, Developmental Biology, and Medicine (miscellaneous) as of 2023, indicating its critical role in shaping contemporary scientific discourse. The journal ranks notably within the top 10% in multiple Scopus categories, indicating its commitment to publishing pioneering research that addresses pressing challenges in regenerative therapies. Addressing the dynamic convergence of disciplines, npj Regenerative Medicine is poised to not only impact academic thought but also translate into clinical applications, making it a pivotal resource for those invested in the future of medicine.

Organogenesis

Pioneering Research in Embryology and Beyond.
Publisher: TAYLOR & FRANCIS INCISSN: 1547-6278Frequency: 4 issues/year

Organogenesis is a leading journal published by Taylor & Francis Inc, dedicated to advancing the field of developmental biology and regenerative medicine. With an ISSN of 1547-6278 and E-ISSN 1555-8592, this journal spans an extensive research scope that includes embryology, transplantation, and biomedical engineering, distinguishing itself as a crucial platform for researchers and practitioners alike. Its impact is reflected in its performance across various categories in 2023, earning Q3 rankings in Biomedical Engineering and Embryology, Q4 in Developmental Biology, and Q2 in Transplantation, showcasing its reputable standing among peer journals. Moreover, with Scopus rankings indicating strong positioning in the fields of medicine and biochemistry, Organogenesis is essential for those looking to publish or stay updated on pioneering research. The journal facilitates rigorous peer-review and offers a forum for disseminating innovative findings, making it an invaluable resource for academics, professionals, and students committed to understanding the complexities of organism development.

Indian Journal of Hematology and Blood Transfusion

Advancing Hematology: Unveiling Insights for Better Blood Health
Publisher: SPRINGER INDIAISSN: 0971-4502Frequency: 4 issues/year

Indian Journal of Hematology and Blood Transfusion, published by SPRINGER INDIA, serves as a leading platform for disseminating original research, reviews, and case studies in the field of hematology. With an ISSN of 0971-4502 and E-ISSN 0974-0449, this journal has been instrumental in advancing knowledge from 2000 to 2024, providing insights into critical issues surrounding blood disorders and transfusion practices. Currently ranked in the Q3 category for Hematology for 2023, it reflects a commitment to high-quality scientific content amidst a competitive landscape where it ranks 97/137 in Scopus for Medicine - Hematology, placing it in the 29th percentile of its peers. The journal primarily addresses a diverse readership, including researchers, healthcare professionals, and students, aiming to foster innovation and collaboration within the field. Although it operates under a subscription model, access options for individual articles and institutional subscriptions ensure that valuable research is disseminated widely to enhance medical practice and education in hematology.